Internal Medicine pract. at Gustave Roussy, in Early Drug Unit. News therapies solutions to be proposed to all pts with hard-to-treat diseases. Tweet my owns.
Paris, France
Joined April 2017
- Tweets45
- Following146
- Followers132
- Likes64
Knowing better about new drugs means above all better understanding how healthy organs work. Thnks to @DrMichaelColli1 and GI team for this comprehensive report in @EXCLIJournal
Emblematic P1 + GI expert coop for
@GustaveRoussy @Hopital_Bicetre @UnivParisSaclay @LillyPad
#Notch inhibitors induce diarrhea, hypercrinia and secretory cell #metaplasia in the #humanColon
The authors of excli.de/index.php/excli/art… studied #intestinal #toxicity of the Notch inhibitor #LY3039478 in cohort study.
@Hopital_Bicetre @UnivParisSaclay @GustaveRoussy @LillyPad
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited cancerdiscovery.aacrjournals…
#ASH20 : Yi Lin: CAR-T for R/R MM study CRB-401 longer FU of P1 with idecabtagene vicleucel raise the median OS = 34.2 mo in a highly prett / selected pop of pts. In the P2 the median OS is 19.4 mo and median PFS 8.8 mo. Safety update unravel frequent neutropenia (G3/4: 88.7%)
#ASH20 Sham Mailankody: FIH anti-bcma ALLO-CAR-T cells in r/r multiple myeloma; 90% treated in 5 days of enrollement ! Dose cells responses / up-to 60% ORR => Most than encouraging.
1
Phase 3, RoCHOP vs CHOP, no improvement in PFS and OS. Significant and limit (p=0.04) prolongation of DOR in the RoCHOP arm unreavaling minimal but real therapeutic effect. Important data to move forward with new phases 3 integrative new drugs.
1
Sortie de confinement, ou la somme de tous les dangers laviedesidees.fr/Sortie-de-c… via @laviedesidees
Similar impressive efficacy (ORR 69%) irrespectively of status refractory to immunochemo in FL pts. Any issue of safety. Feeling as the best chemofree option in hard to treat FL patients up-to-date.
Jean-Marie Michot from @GustaveRoussy at #ASH18 presented data concluding avadomide in combination with obinutuzumab was well-tolerated with promising clinical activity in patients with relapsed/refractory #FL #lymsm #lymphoma
2
Impressive responses rates in this heavily pretreated FL population (3 prior lines and half of refractory to ritux), a population more difficult to treat compare with AUGMENT study. Yes to Make sense for favorable higher activity than len.
Dr Michot presents an interesting study of Cc-122 (avadomide) and obinutuzumab in r/r B-cell lymphoma - impressive response rates and pretty well tolerated. Could it be better than Len? #EHA18 #lymSM
1
IgIV do not influence the course ITP in children > 6 months, great clinical trial
Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial bloodjournal.org/content/132…
Further trials are need for Dara and WM
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells - Paulus - - British Journal of Haematology - Wiley Online Library onlinelibrary.wiley.com/doi/…
Circulating Tumor DNA Measurements is overcoming all classical prognostic factors in DLBCL !!! probably a shift paradigm, and changes in routine in few times (hope) ascopubs.org/doi/pdf/10.1200…
2
FL is not driven by BTK. Is probably today much more drugable by some epidrugs. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results ... DAWN Study: Journal of Clinical Oncology: Vol 36, No 23 ascopubs.org/doi/full/10.120…
PD1 inhibition is not a way to control cancer in all tumor types. A need for new immuno combo in specific tumor types
Rapid Progression of Adult T-Cell Leukemia–Lymphoma after PD-1 Inhibitor Therapy | NEJM nejm.org/doi/full/10.1056/NE…
1
The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy ard.bmj.com/content/77/2/162
Des grillages anti-migrants en plein Paris, métro Stalingrad. Le trottoir n’est plus un espace public ? #parisvillerefuge
